Oligonucleotide

NeuBase Therapeutics Announces Positive, Preclinical Data Validating its Novel Genetic Therapy PATrOL™ Platform

Tuesday, March 31, 2020 - 12:00pm

ET

Key Points: 
  • ET
    PITTSBURGH, March 31, 2020 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq:NBSE) (NeuBase or the Company), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies to address genetic diseases, today announced positive preclinical data from its pharmacokinetics studies in non-human primates (NHPs) and in vitro pharmacodynamics data in patient-derived cell lines.
  • NeuBase Therapeutics, Inc. will discuss these data and next steps for development during a webcasted conference call with slides today, March 31, 2020, at 8:00 a.m.
  • NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.
  • Using PATrOL technology, NeuBase aims to first tackle rare, genetic neurological disorders.

NeuBase Therapeutics Reports Financial Results for the First Fiscal Quarter of 2020

Thursday, March 26, 2020 - 8:05pm

Next week, we plan to announce the results from a pharmacokinetic study in non-human primates, as well as pharmacodynamic data in patient-derived cell lines.

Key Points: 
  • Next week, we plan to announce the results from a pharmacokinetic study in non-human primates, as well as pharmacodynamic data in patient-derived cell lines.
  • The Company believes that its current cash balance will provide sufficient capital to fund operations through the end of fiscal year 2020.
  • NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.
  • These views involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements.

DGAP-News: Secarna Pharmaceuticals announces the acquisition of LNAplusTM based antisense drug candidates by Lipigon Pharmaceuticals

Monday, March 23, 2020 - 8:01am

Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.

Key Points: 
  • Under this agreement, Lipigon acquires certain antisense drug candidates, which were developed with Secarna's proprietary LNAplusTM platform, including the corresponding patent portfolio.
  • The antisense oligonucleotide candidates targeting the ANGPTL gene family for the treatment of cardiovascular and metabolic diseases were previously generated by Secarna and Lipigon under a target validation and drug discovery collaboration.
  • Going forward, Lipigon will fund and continue the development of the acquired assets and Secarna receives payments customary for such a transaction.
  • Inhibiting the ANGPTL gene family members ANGPTL3 and ANGPTL4 with Secarna's LNAplusTM based antisense oligonucleotides has shown to positively affect plasma lipid levels.

Global Oligonucleotide Synthesis Market Analysis, Trends, and Forecasts 2019-2025 - ResearchAndMarkets.com

Friday, March 13, 2020 - 10:49am

The "Oligonucleotide Synthesis - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Oligonucleotide Synthesis - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • Oligonucleotide Synthesis market worldwide is projected to grow by US$1.6 Billion, driven by a compounded growth of 10.6%.
  • Synthesized Oligonucleotides, one of the segments analyzed and sized in this study, displays the potential to grow at over 11.1%.
  • Poised to reach over US$1.6 Billion by the year 2025, Synthesized Oligonucleotides will bring in healthy gains adding significant momentum to global growth.

NeuBase Therapeutics Receives Notification of Deficiency from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

Friday, February 21, 2020 - 9:50pm

Under Nasdaqs listing rules, NeuBase has 60 calendar days from the date of the Notice to submit a plan to regain compliance.

Key Points: 
  • Under Nasdaqs listing rules, NeuBase has 60 calendar days from the date of the Notice to submit a plan to regain compliance.
  • NeuBase expects to file its Form 10-Q within the timeline prescribed by Nasdaq.
  • In addition, NeuBase announced today that it has engaged Marcum LLP as its independent registered public accounting firm, effective February 20, 2020.
  • NeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides.

Global Synthetic Biology Market is Projected to Reach USD 19.8 Billion by 2025 from USD 6.8 Billion in 2020, at a CAGR of 23.9% - ResearchAndMarkets.com

Wednesday, February 19, 2020 - 1:27pm

The synthetic biology market is projected to reach USD 19.8 billion by 2025 from USD 6.8 billion in 2020, at a CAGR of 23.9%.

Key Points: 
  • The synthetic biology market is projected to reach USD 19.8 billion by 2025 from USD 6.8 billion in 2020, at a CAGR of 23.9%.
  • However, rising biosafety, biosecurity, and ethical concerns related to synthetic biology are likely to hamper the growth of this market.
  • In 2019, the oligonucleotides and synthetic DNA segment is expected to register the highest CAGR during the forecast period.
  • The synthetic biology market is divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.

Oligonucleotide Synthesis Market Outlook to 2025 - Growing Adoption of Synthesized Oligonucleotides in Diagnostics & Clinical Applications - ResearchAndMarkets.com

Friday, January 31, 2020 - 11:12am

The global oligonucleotide synthesis market is expected to grow at a CAGR of 10.4% from 2019 to 2025 to reach $3.9 billion by 2025.

Key Points: 
  • The global oligonucleotide synthesis market is expected to grow at a CAGR of 10.4% from 2019 to 2025 to reach $3.9 billion by 2025.
  • In 2019, oligonucleotide synthesis products segment is estimated to account for the largest share of the global oligonucleotide synthesis market.
  • On the basis of application, research applications segment accounted for the largest share of the overall oligonucleotide synthesis market in 2019.
  • North America commanded the largest share of the global oligonucleotide synthesis market in 2019, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

The Asia Pacific oligonucleotide synthesis market is expected to reach US$ 872.98 Mn in 2027 from US$ 334.26 Mn in 2018

Monday, January 20, 2020 - 6:10pm

NEW YORK, Jan. 20, 2020 /PRNewswire/ -- The Asia Pacific oligonucleotide synthesis market is expected to reach US$ 872.98 Mn in 2027 from US$ 334.26 Mn in 2018.

Key Points: 
  • NEW YORK, Jan. 20, 2020 /PRNewswire/ -- The Asia Pacific oligonucleotide synthesis market is expected to reach US$ 872.98 Mn in 2027 from US$ 334.26 Mn in 2018.
  • The growth of the oligonucleotide synthesis market is primarily attributed to the growing use of synthesized oligonucleotides and government support for biotechnology research in Asia Pacific.
  • Also, the segment is also anticipated to witness growth at a significant rate during the forecast period, 2018 to 2027.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

$3.9Bn Oligonucleotide Synthesis Industry Analysis, 2019-2025

Thursday, January 16, 2020 - 7:00pm

DUBLIN, Jan. 16, 2020 The "Oligonucleotide Synthesis Market by Product and Service (Synthesizer, Custom Oligonucleotide Synthesis Service, Probes, Primers, Linkers and Adaptor, Reagents), Application (Research, Therapeutics, Diagnostics), and End User - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Jan. 16, 2020 The "Oligonucleotide Synthesis Market by Product and Service (Synthesizer, Custom Oligonucleotide Synthesis Service, Probes, Primers, Linkers and Adaptor, Reagents), Application (Research, Therapeutics, Diagnostics), and End User - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The global oligonucleotide synthesis market is expected to grow at a CAGR of 10.4% from 2019 to 2025 to reach $3.9 billion by 2025.
  • In 2019, oligonucleotide synthesis products segment is estimated to account for the largest share of the global oligonucleotide synthesis market.
  • On the basis of application, research applications segment accounted for the largest share of the overall oligonucleotide synthesis market in 2019.

Aro Biotherapeutics and Ionis Enter Licensing and Collaboration Agreement Focused on Cell-Specific Delivery of Antisense Oligonucleotides

Thursday, January 9, 2020 - 12:00pm

Aro Biotherapeutics Company announces it has entered a licensing and collaboration agreement with Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, through which Ionis will use Aros CENTYRIN technology to develop targeted cell- and tissue- specific delivery of antisense oligonucleotides (ASOs).

Key Points: 
  • Aro Biotherapeutics Company announces it has entered a licensing and collaboration agreement with Ionis Pharmaceuticals, Inc., the leader in RNA-targeted therapeutics, through which Ionis will use Aros CENTYRIN technology to develop targeted cell- and tissue- specific delivery of antisense oligonucleotides (ASOs).
  • Ionis will leverage this unique technology to develop novel ASO-Centyrin combination drug candidates targeting a variety of diseases with high unmet medical need.
  • Under the terms of the agreement, the two companies have agreed to jointly work towards advancing a defined number of ASO-Centyrin drug conjugates.
  • Aro will be responsible for Centyrin discovery and will collaborate with Ionis to create lead ASO-Centyrin drug conjugates for further development.